US009511121B2

(12) **United States Patent**
Imran

(10) **Patent No.: US 9,511,121 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **METHOD FOR DELIVERING EXENATIDE TO A PATIENT IN NEED THEREOF**

(71) Applicant: **Rani Therapeutics, LLC**, San Jose, CA (US)

(72) Inventor: **Mir Imran**, Los Altos Hills, CA (US)

(73) Assignee: **Rani Therapeutics, LLC**, San Jose, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/620,827**

(22) Filed: **Feb. 12, 2015**

(65) **Prior Publication Data**

US 2015/0238571 A1 Aug. 27, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/538,748, filed on Jun. 29, 2012, now Pat. No. 8,969,293, and a continuation-in-part of application No. 12/978,233, filed on Dec. 23, 2010, now Pat. No. 8,721,620, and a continuation-in-part of application No. 12/978,164, filed on Dec. 23, 2010, now Pat. No. 8,759,284, and a continuation-in-part of application No. 12/978,301, filed on Dec. 23, 2010, now Pat. No. 8,562,589.

(60) Provisional application No. 61/571,634, filed on Jun. 29, 2011, provisional application No. 61/571,641, filed on Jun. 29, 2011.

(51) **Int. Cl.**

A61K 38/26	(2006.01)
A61M 25/10	(2013.01)
A61M 5/00	(2006.01)
A61K 9/00	(2006.01)
A61K 38/28	(2006.01)
A61K 45/06	(2006.01)
A61M 31/00	(2006.01)
A61K 9/48	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/26*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 38/28*** (2013.01); ***A61K 45/06*** (2013.01); ***A61M 5/00*** (2013.01); ***A61M 25/10*** (2013.01); *A61K 9/4808* (2013.01); *A61M 31/002* (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/26

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,788,322	A	1/1974	Michaels
4,425,117	A	1/1984	Hugemann et al.
4,596,819	A	6/1986	Nicolaides et al.
4,663,308	A	5/1987	Saffran et al.
4,781,685	A	11/1988	Lehmann et al.
5,129,915	A	7/1992	Cantenys
5,137,669	A	8/1992	Leonard et al.
5,217,449	A	6/1993	Yuda et al.
5,271,945	A	12/1993	Yoshioka et al.
5,474,785	A	12/1995	Wright et al.
5,674,205	A	10/1997	Pasricha et al.
5,683,435	A	11/1997	Truex et al.
5,750,926	A	5/1998	Schulman et al.
5,795,591	A	8/1998	Lee et al.
5,849,327	A	12/1998	Berliner et al.
5,904,935	A	5/1999	Eckenhoff et al.
5,987,358	A	11/1999	Sosebee et al.
6,369,073	B1	4/2002	Giannessi et al.
6,632,216	B2	10/2003	Houzego et al.
6,645,988	B2	11/2003	Phillips
6,656,155	B2	12/2003	Freyman
6,743,211	B1	6/2004	Prausnitz et al.
6,975,906	B2	12/2005	Rusin et al.
7,083,578	B2	8/2006	Lewkowicz et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101511305 A	8/2009
EP	2196131 A1	6/2010

(Continued)

OTHER PUBLICATIONS

European search report and search opinion dated Mar. 12, 2015 for EP Application No. 12803759.5.

(Continued)

Primary Examiner — Gyan Chandra

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

25 Claims, 46 Drawing Sheets